A Wall Street analyst described the launch of Biogen’s new Alzheimer’s disease drug as “potentially the worst drug launch of all time.”
The critical note from Raymond James analyst Steven Seedhouse came in response to the news that Aduhelm, the company’s new treatment for the neurodegenerative disease, generated only $300,000 in sales in the third quarter of the year. It was approved by U.S. regulators back in June.
“We...
"had" - Google News
October 21, 2021 at 10:59PM
https://ift.tt/3E1fECx
Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says - MarketWatch
"had" - Google News
https://ift.tt/2KUBsq7
https://ift.tt/3c5pd6c
Bagikan Berita Ini
0 Response to "Biogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says - MarketWatch"
Post a Comment